Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Update

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a large increase in short interest in March. As of March 15th, there was short interest totalling 4,600 shares, an increase of 39.4% from the February 29th total of 3,300 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 8,700 shares, the days-to-cover ratio is currently 0.5 days.

Anebulo Pharmaceuticals Price Performance

ANEB stock opened at $2.87 on Friday. Anebulo Pharmaceuticals has a fifty-two week low of $1.62 and a fifty-two week high of $4.05. The stock has a market capitalization of $73.57 million, a price-to-earnings ratio of -6.83 and a beta of -1.02. The business’s fifty day moving average price is $2.63 and its two-hundred day moving average price is $2.55.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last released its quarterly earnings results on Tuesday, February 13th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). Research analysts expect that Anebulo Pharmaceuticals will post -0.47 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Anebulo Pharmaceuticals stock. Tower Research Capital LLC TRC boosted its stake in shares of Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) by 241.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 20,851 shares of the company’s stock after acquiring an additional 14,750 shares during the period. Tower Research Capital LLC TRC owned 0.08% of Anebulo Pharmaceuticals worth $64,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 28.40% of the company’s stock.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.